Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Other Accumulated Expenses (2016 - 2025)

Orthopediatrics (KIDS) has disclosed Other Accumulated Expenses for 10 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 17.55% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 17.55% increase, with the full-year FY2025 number at $11.4 million, up 17.55% from a year prior.
  • Other Accumulated Expenses was $11.4 million for Q4 2025 at Orthopediatrics, up from $10.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $11.8 million in Q2 2025 to a low of $1.5 million in Q3 2021.
  • A 5-year average of $6.3 million and a median of $5.8 million in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 67.83% in 2021, then surged 157.45% in 2022.
  • Orthopediatrics' Other Accumulated Expenses stood at $2.0 million in 2021, then soared by 145.98% to $5.0 million in 2022, then skyrocketed by 47.29% to $7.4 million in 2023, then surged by 30.69% to $9.7 million in 2024, then rose by 17.55% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's Other Accumulated Expenses are $11.4 million (Q4 2025), $10.9 million (Q3 2025), and $11.8 million (Q2 2025).